Impact Factor
3.35
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.10
275 total citations
h5-index
25
h5 depth signal
Cited share
81.8%
81 of 99
Total citations
275
Citation footprint
Metric signal
2.30
External metric anchor
Self-citation
0.7%
2 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
170
China
138
Germany
35
France
23
Canada
22
Citing Fields of Research
Immunology
444
Oncology
160
Immunotherapy
103
Lung Cancer
42
Lymphomas
29
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,347
Articles tracked across the journal lifetime
Indexed publication set
99
81 cited publications
Last 12 months
40
3.6 publications/month
Open access share
15.0%
6 OA publications in the last year
Leading citing country
United States
170 citing publications
Leading citing field
Immunology
444 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v20n1,Jan. 1997-
v20n1,Jan. 1997-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Oncology
Lung Cancer
Liver & Colon Cancer
Issuing & Sponsoring Bodies
Contributor
Society for Biological Therapy
Broad Categories
Allergy and Immunology
Neoplasms
Therapeutics
Immunology
MeSH Descriptors
Immunotherapy
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/cji.0000000000000623
Open DOI
Area Deprivation Index and Survival Outcomes for Patients With Metastatic Solid Tumors Treated With Immune Checkpoint Inhibitors in the United States
Due to increasing evidence that socioeconomic deprivation influences cancer outcomes through biological effects and care disparities, this single-institution retrospective study estimated associations between neighborhood-level socioecon...
02
DOI 10.1097/cji.0000000000000627
Open DOI
Pembrolizumab-Induced Sarcoidosis-Like Immune-Related Adverse Events: A Pooled Analysis of Published Cases and Report of a Novel Manifestation Involving Phosphocalcic Metabolism
Immune checkpoint inhibitors such as pembrolizumab can trigger immune-related adverse events, including rare sarcoidosis-like reactions (DISR), whose immunopathogenesis and clinical spectrum remain incompletely defined. We conducted a sy...
03
DOI 10.1097/cji.0000000000000624
Open DOI
Immunostaining of p53 Is Associated With Efficacy of Anti-PD-1 Immune Checkpoint Inhibitors in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Current evidence demonstrates the efficacy of anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) in patients with recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC), but only a limited number of ...
04
DOI 10.1097/cji.0000000000000625
Open DOI
Association Between Neoadjuvant Immunochemotherapy Efficacy and Pathologic Characteristics in dMMR Gastric/Gastroesophageal Junction Adenocarcinoma
Neoadjuvant immunotherapy (NAIC) is feasible and associated with a high rate of pathologic complete response (pCR) in deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) gastric and gastroesophageal junction cancers ...
05
DOI 10.1097/cji.0000000000000626
Open DOI
Immune Checkpoint Inhibitors After Chemoradiation in Unresectable Non–Small Cell Lung Cancer: Survival Outcomes From a Tertiary Care Center in Lebanon
To evaluate real-world survival outcomes of consolidation immunotherapy after concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III non–small cell lung cancer (NSCLC) treated at a tertiary cancer center in Lebanon. ...
06
DOI 10.1097/cji.0000000000000619
Open DOI
Erratum: Integrating Bulk RNA-Seq and Spatial Transcriptomics Data to Reveal Distinct Immune Escape Mechanism and Immunotherapy Based on Post-Translational Modification in Head and Neck Squamous Cell Carcinoma
Was not provided for this article.
07
DOI 10.1097/cji.0000000000000620
Open DOI
Dimethyl Fumarate Mediates Glutathione Metabolism to Drive Cuproptosis and Activate the Antitumor Function of CD8+ T Cells Against Liver Cancer
Dimethyl fumarate (DMF) exerts cytoprotective effects via antioxidant pathway activation. Whether it modulates antitumor immunity through novel cell death forms remains unclear. GSH/GSSG levels were measured in HCC and adjacent tissues u...
08
DOI 10.1097/cji.0000000000000622
Open DOI
Clinical Features, Treatment, and Outcomes of Sintilimab-induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
To explore the clinical characteristics of sintilimab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and provide references for prevention, diagnosis, and treatment. Clinical reports of sintilimab-induced SJS/TEN p...
09
DOI 10.1097/cji.0000000000000621
Open DOI
Auranofin Sensitizes Oral Squamous Cell Carcinoma to PD-1 Blockade Through DUSP1-Associated Macrophage Reprogramming
Oral squamous cell carcinoma (OSCC) is frequently refractory to immune checkpoint blockade, in part because the tumor microenvironment is enriched with immunosuppressive, M2-like tumor-associated macrophages. Auranofin (ARN), an FDA-appr...
10
DOI 10.1097/cji.0000000000000618
Open DOI
Brief Communication: LSD1 Inhibition Enhances Susceptibility of Primary AML Cells for NK Cell-Mediated Killing
Acute myeloid leukemia (AML) is a hematological malignancy associated with poor prognosis. Recent developments in natural killer (NK) cell-based immunotherapies have resulted in the robust expansion of NK cells with enhanced cytotoxicity...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Official journal of the Society for Biological Therapy.